Ciclesonide for the Treatment of Airway Hyperresponsiveness

This study has been completed.
Information provided by (Responsible Party):
Takeda Identifier:
First received: January 21, 2009
Last updated: February 4, 2013
Last verified: February 2013

The study objective is to investigate in a placebo-controlled, double-blind manner the effect of inhaled corticosteroid (ciclesonide) on airway hyperresponsiveness measured as having PD15 mannitol. Treatment medication will be administered as follows: 320 microgram ciclesonide or placebo will be inhaled once daily. The study duration consists of a treatment period of 4 weeks. The study will provide further data on safety of ciclesonide.

Condition Intervention Phase
Drug: Ciclesonide
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Ciclesonide for the Treatment of Airway Hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A Double-blind, Randomized, Parallel Group Study.

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change of hyper-responsiveness to mannitol assessed by PD15FEV1 after 4 weeks of treatment with ciclesonide vs Placebo [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • RDR mannitol (response-dose-ratio = %fall in FEV1 / provocation dose given) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Responsiveness to methacholine (PD20FEV1 ) and RDR methacholine after 4 weeks of treatment [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Level of exhaled nitric oxide after 4 weeks of treatment [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • mean improvement of FEV1 and PEF, mean change of the asthma control questionnaire ACQ (Juniper) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Mean change of ACQ after 4 weeks of treatment [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Mean change of AQLQ after 4 weeks of treatment [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Mean change of symptoms, rescue medication use, nocturnal awakening according to GINA after 4 weeks of treatment [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
  • Exacerbation rates during the 4 weeks of treatment [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 64
Study Start Date: September 2008
Study Completion Date: October 2011
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Ciclesonide 320µg
Drug: Ciclesonide
320µg Ciclesonide versus Placebo
Placebo Comparator: 2
Drug: Placebo


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Referred to the pulmonology department of the university hospital Basel because of suspected asthma defined as respiratory symptoms like wheezing or cough or chest tightness.
  2. Asthma symptoms partly controlled according to GINA (October 2006) 1 week prior to randomization
  3. FEV1 ≥ 70% predicted
  4. 18 - 70 years old

Exclusion Criteria:

  1. Smoker and ex-smoker with >10 pack years
  2. COPD
  3. Upper respiratory tract infection within the past 4 weeks.
  4. ICS or oral steroids during the previous month before inclusion
  5. b-blockers within the past 4 weeks
  6. Current treatment with medication as defined in section concomitant medication (ICS other than study medication, ß-blockers)
  7. Pregnancy
  8. Known malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00826969

Basel, Switzerland, 4031
Sponsors and Collaborators
Study Chair: Nycomed Clinical Trial Management Headquarter
  More Information

No publications provided

Responsible Party: Takeda Identifier: NCT00826969     History of Changes
Other Study ID Numbers: BY9010/CH-101, U1111-1137-3949
Study First Received: January 21, 2009
Last Updated: February 4, 2013
Health Authority: Switzerland: Swissmedic

Keywords provided by Takeda:

Additional relevant MeSH terms:
Anti-Allergic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on October 09, 2015